NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Tracer Biotechnologies

Tracer Biotechnologies

Private
New York City, New YorkHealthcare & Life Scienceshttps://tracerbio.com/

Last Round

Series A

Dec 19, 2024

Total Funding Raised

$10M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Tracer Biotechnologies is a biotechnology company that has developed a platform for ultrasensitive circulating tumor DNA (ctDNA) monitoring to detect cancer, measure treatment response, and track recurrence.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Clinical Trials, Healthcare Analytics

Business Model

B2B

Customer Profile

Usage-Based SaaS, Services & Consulting

AI Layer

Application

Keywords

minimal residual diseaseMRDcirculating tumor DNActDNAliquid biopsycancer monitoringdigital PCRdPCRNGSnext-generation sequencingdecentralized clinical trialsmolecular diagnosticsprecision oncologyAI diagnosticsclinical trial software

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Tracer Biotechnologies Comparables

Compare Tracer Biotechnologies with similar companies based on industry and business-model similarity.

Tracer Biotechnologies comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
CareDx
77%
NeoGenomics Inc
75%
Veracyte
74%

Tracer Biotechnologies Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ADec 19, 2024

Tracer Biotechnologies Investors

Notable investors and investment history

Tracer Biotechnologies investors
InvestorRounds
Great Oaks Venture CapitalSeries A
Impatient VenturesSeries A
Quiet VenturesSeries A
Caffeinated CapitalSeries A
ExorSeries A
Pareto HoldingsSeries A
Quiet CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 14, 2026

    Monthly visitors grew 4231% MoM, from 36 to 1.6K.

  • Jun 3, 2025

    Developing blood-based MRD tests for solid tumors in partnership with QIAGEN.

Tracer Biotechnologies Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Tracer Biotechnologies Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Tracer Biotechnologies's valuation, stock price, and market status.

Firmographic Details

HeadquartersNew York City, New York
Employee Range7
Year Founded2021
Last FundingDec 19, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.